Allopurinol use and risk of acute coronary syndrome in gout patients: a population-based cohort study in Sweden.

ABSTRACT:

Objectives

To investigate the impact of allopurinol use on the risk of first-ever acute coronary syndrome (ACS) event in patients with gout.

Methods

Using national and regional register data, we included all patients with a gout diagnosis at primary or specialised care in Western Sweden in the period 2007-2017 (n=18 862; 67% male patients). Patients with a prior history of coronary heart disease (CHD) were excluded. Follow-up started at the first gout diagnosis and ended at the first-ever ACS event, death or study end. The main outcome was the risk of first-ever ACS in: (1) allopurinol users versus non-users, by defining three categories of allopurinol exposure: exposed to 100 mg, >100 mg and no exposure (reference) and (2) allopurinol initiators (within 125 days) versus lon

SUBMITTER: Drivelegka P 

PROVIDER: S-EPMC11873353 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature